Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484525 | 0.89 | PPARD (0.54) | PPARDPPARGPPARAHTTALDH1A1 | |
| SCHEMBL4184065 | 0.88 | PPARD (0.52) | PPARDPPARGPPARAHTTALDH1A1 | |
| SCHEMBL4182865 | 0.87 | PPARD (0.53) | PPARDPPARGPPARAHTTALDH1A1 | |
| SCHEMBL13774909 | 0.86 | PPARD (0.53) | PPARDPPARGPPARAHTTALDH1A1 | |
| SCHEMBL4621511 | 0.85 | ALDH1A1 (0.52) | PPARDPPARGPPARAHTTALDH1A1 | |
| SCHEMBL24474657 | 0.80 | PPARD (0.53) | PPARDPPARGPPARAHTTALDH1A1 | |
| SCHEMBL4186855 | 0.80 | PPARD (0.55) | PPARDPPARGPPARAHTTALDH1A1 | |
| SCHEMBL12402754 | 0.79 | PPARG (0.45) | PPARDPPARGPPARAHTTALDH1A1 | |
| SCHEMBL1244071 | 0.79 | PPARG (0.52) | PPARDPPARGPPARAHTTALDH1A1 | |
| SCHEMBL4182920 | 0.78 | LMNA (0.42) | HTTALDH1A1KDM4EKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394841-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-03-12 | — | — | US | disclosed |
| US-8394841-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-03-12 | — | — | US | disclosed |
| US-20100035944-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-02-11 | — | — | US | disclosed |
| US-20100035944-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-02-11 | — | — | US | disclosed |
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | disclosed |
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | disclosed |
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | disclosed |
| WO-2008103501-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2008-08-28 | — | — | WO | disclosed |
| EP-1945620-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2008-07-23 | — | — | EP | disclosed |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| WO-2007056366-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
| EP-1748993-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005116000-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035944-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GRK5 | PPARD 378/4885PPARG 106/4885PPARA 396/4885 |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.